![Scott Biller](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Scott Biller
Director/Board Member at
FOGHORN THERAPEUTICS INC.
Net worth: - $ as of 30/06/2026
Profile
Scott Biller is currently Director at OMass Therapeutics Ltd. since 2022, Independent Director at Foghorn Therapeutics, Inc. since 2020, Director at Remix Therapeutics, Inc. since 2020, and Director at Rome Therapeutics, Inc. since 2021.
Formerly, Dr. Biller was Chief Scientific Officer at Agios Pharmaceuticals, Inc. from 2010 to 2019, Vice President & Head-Global Discovery Chemistry at Novartis Institutes for Biomedical Research, Inc. from 2003 to 2010, and VP-Pharmaceutical Candidate Optimization at Bristol-Myers Squibb Pharmaceutical Research Institute from 2001 to 2003.
Education includes an undergraduate degree from Massachusetts Institute of Technology in 1976 and a doctorate from California Institute of Technology in 1981.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 24/06/2026 | 0 ( -.--% ) | - $ | 30/06/2026 |
Scott Biller active positions
| Companies | Position | Start |
|---|---|---|
| FOGHORN THERAPEUTICS INC. | Director/Board Member | 09/01/2020 |
Remix Therapeutics, Inc.
 Remix Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company develops molecule therapies to modulate RNA processing and address the underlying drivers of diseases | Director/Board Member | 01/06/2020 |
Rome Therapeutics, Inc.
 Rome Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops novel therapies for cancer and autoimmune diseases | Director/Board Member | 01/02/2021 |
OMass Therapeutics Ltd.
 OMass Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Develops native mass spectrometry platform | Director/Board Member | 01/01/2022 |
Former positions of Scott Biller
| Companies | Position | End |
|---|---|---|
| AGIOS PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 31/12/2019 |
Novartis Institutes for Biomedical Research, Inc.
 Novartis Institutes for Biomedical Research, Inc. Miscellaneous Commercial ServicesCommercial Services Conducts biomedical researches | Corporate Officer/Principal | 01/09/2010 |
Bristol-Myers Squibb Pharmaceutical Research Institute | Corporate Officer/Principal | 01/07/2003 |
Training of Scott Biller
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
80
1st degree connections
9
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 9 |
|---|---|
Agios Pharmaceuticals, Inc.
 Agios Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Discovers and develops therapeutics | Health Technology |
Massachusetts Institute of Technology
 Massachusetts Institute of Technology Finance/Rental/LeasingFinance Functions as a College/University | Finance |
California Institute of Technology
 California Institute of Technology Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Novartis Institutes for Biomedical Research, Inc.
Novartis Institutes for Biomedical Research, Inc. Miscellaneous Commercial ServicesCommercial Services Conducts biomedical researches | Commercial Services |
Bristol-Myers Squibb Pharmaceutical Research Institute | |
OMass Therapeutics Ltd.
OMass Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Develops native mass spectrometry platform | Commercial Services |
Foghorn Therapeutics, Inc.
 Foghorn Therapeutics, Inc. BiotechnologyHealth Technology Discovers and develops novel drugs to treat cancer and other serious medical disorders | Health Technology |
Rome Therapeutics, Inc.
Rome Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops novel therapies for cancer and autoimmune diseases | Health Technology |
Remix Therapeutics, Inc.
Remix Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company develops molecule therapies to modulate RNA processing and address the underlying drivers of diseases | Health Technology |
- Stock Market
- Insiders
- Scott Biller
Choose MarketScreener 
